Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression

Yang Li 1†, Changqian Zeng 2†, Jialei Hu 1, Yue Pan 1, Yujia Shan 1, Bing Liu 1 and Li Jia 1*

Abstract

Background: Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. The long non-coding RNAs (lncRNAs), emerging as key molecules in human malignancy, has become one of the hot topics in RNA biology. Aberrant O-glycosylation is a well-described hallmark of many cancers. GALNT7 acts as a glycosyltransferase in protein O-glycosylation, involving in the occurrence and development of CRC.

Methods: The microarrays were used to survey the lncRNA and mRNA expression profiles of primary CRC cell line SW480 and metastatic CRC cell line SW620. Cell proliferation, migration, invasion, and apoptosis were assayed. Xenograft mouse models were used to determine the role of lncRNA-SNHG7 in CRC in vivo. In addition, CNC analysis and competing endogenous analysis were used to detect differential SNHG7 and relational miRNAs expression in CRC cell lines.

Results: SNHG7 expression showed a high fold (SW620/SW480) in CRC microarrays. The CRC patients with high expression of SNHG7 had a significantly poor prognosis. Furthermore, SNHG7 promoted CRC cell proliferation, metastasis, mediated cell cycle, and inhibited apoptosis. SNHG7 and GALNT7 were observed for co-expression by CNC analysis, and a negative correlation of SNHG7 and miR-34a were found by competing endogenous RNA (ceRNA) analysis. Further results indicated that SNHG7 facilitated the proliferation and metastasis as a competing endogenous RNA to regulate GALNT7 expression by sponging miR-34a in CRC cell lines. SNHG7 also played the oncogenic role in regulating PI3K/Akt/mTOR pathway by competing endogenous miR-34a and GALNT7.

Conclusion: The CRC-related SNHG7 and miR-34a might be implicated in CRC progression via GALNT7, suggesting the potential usage of SNHG7/miR-34a/GALNT7 axis in CRC treatment.

Keywords: lncRNA-SNHG7, miR-34a, GALNT7, Progression
Background
Colorectal cancer (CRC), a high-risk digestive tract tumor, is one of the most frequent malignant tumors worldwide [1]. The pathogenesis of CRC involves multiple factors, including environmental and genetic variables, while detailed molecular mechanisms remain unclear [2]. Hence, a better understanding of the mechanisms and finding predictive biomarkers are urgently needed to detect CRC.

Long non-coding RNAs (lncRNAs) are over 200 nucleotides in length without protein-coding capacity. Mounting evidence demonstrates that IncRNAs may be emerged as essential regulators in many biological processes [3]. MicroRNAs (miRNAs, 20–25 nt) bind to the 3′-untranslated region (3′-UTR) of mRNA, catalyzed by the RNA-induced silencing complex (RISC), which subsequently cause degradation of the target mRNA or inhibition of its translation [4]. Recent literature has documented that IncRNAs enrich in the cytoplasm typically participate in post-transcriptional regulation by interacting with miRNAs or mRNAs [5], and play an active role in regulating miRNA availability within the cell and form regulatory networks [6].

SNHG7 (small nucleolar RNA host gene 7) is one of the recognized IncRNAs, which is located on chromosome 9q34.3, with a length of 2176 bp [7]. SNHG7 promotes the proliferation, migration, and invasion and inhibits apoptosis in many cancers, such as malignant pleural mesothelioma [8], breast cancer [9], chromophobe renal cell carcinoma [10], and lung cancer [11]. However, the clinical significance and biological mechanisms of SNHG7 in the progression of CRC remain largely to be elucidated.

Glycosylation is a common and highly diverse form of protein modification [12] and plays a pivotal role in malignancy. As a member of the acetylgalactosaminyltransferase family, GALNT7 materializes a certain biological effect by regulating the interaction between tumor cells and the extracellular environment. GALNT7 expression is a well-described hallmark of many cancers such as cervical cancer, pancreatic cancer, and laryngocarcinoma [13–15]. Recently, promising evidence has shown that the mRNA encoded by competing endogenous RNA (ceRNA) genes could be involved in distinct biological processes. Exploration of the function and involvement of IncRNA-miRNA-mRNA crosstalk may become a key development in exploring the molecular mechanisms of cancer.

In the present study, differences between the IncRNA and mRNA expression profiles of CRC cell lines were assessed in IncRNA microarray. High level of IncRNA-SNHG7 was correlated with tumor size, lymphatic metastasis, distant metastasis, and tumor stage. In addition, we investigated whether SNHG7 directly bound to miR-34a to de-repress the target gene of GALNT7 and participated in the regulation of CRC progression via PI3K/Akt/mTOR pathway. Our findings provided further evidence that SNHG7 regulated GALNT7 by sponging miR-34a and contributed to CRC progression, which might provide novel insights into the function of IncRNA-driven in CRC.

Methods
Clinical samples, cell lines, and culture condition
Two independent cohorts were enrolled. Cohort 1: Fresh CRC and adjacent tissues were collected from 53 patients between March 2015 and January 2018. Cohort 2: Liquid nitrogen storage tissues from 70 CRC patients who initially underwent tumor between January 2011 and May 2012. Tumor tissues and adjacent tissues (5 cm from the tumor edge) were obtained at the First Affiliated Hospital of Dalian Medical University (Dalian, China). None of the patients received any chemotherapy or radiation treatment prior to the surgery. The study and its informed consent have been examined and certified by the Ethics Committee.

CRC cell lines caco2, SW480, SW620, Hct116, and LoVo, and human normal colon epithelial cell line (FHC) were purchased from KeyGEN Company (Nanjing, China). The primary CRC cell line was established from a primary carcinoma of the CRC. Cells were cultured in 90% DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (Gibco) and 1% penicillin–streptomycin (HyClone, Logan, UT, USA) at 37 °C with 5% CO2.

RNA labeling and array hybridization
Labeled sample and array hybridization were analyzed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). The rRNA was removed, and mRNA was purified from total RNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each specimen was amplified and transcribed into fluorescent cRNA (Arraystar Flash RNA Labeling Kit, Arraystar). The labeled cRNAs were purified using RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg cRNA) were determined by NanoDrop ND-1000. Each labeled cRNA (1 μg) was fragmented by adding 5 μl 10× Blocking Agent and 1 μl of 25× Fragmentation Buffer. The mixture was heated at 60 °C for 30 min, and 25 μl 2× GE Hybridization buffer was added. Hybridization solution (50 μl) was applied and assembled to the IncRNA expression microarray slide. The slides were treated for 17 h at 65 °C in an Agilent Hybridization Oven. The hybridized arrays were scanned by the Agilent DNA Microarray Scanner (part number G2505C).
Microarray and computational analysis
LncRNA expression profiles of SW480 and SW620 (n = 3/group) were used to synthesize double-stranded cDNA and hybridized to the 8x60K. RNA quantity and quality were measured by NanoDrop ND-1000. RNA integrity was assessed by standard denaturing agarose gel electrophoresis or Agilent 2100 Bioanalyzer. Arraystar Human LncRNA Microarray V4.0 was designed for the global profiling of human LncRNAs and protein-coding transcripts.

Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed with GeneSpring GX v12.1 software package (Agilent Technologies). Differentially expressed IncRNAs and mRNAs were identified through fold change/p value/FDR filtering (fold change ≥ 2.0, a P value ≤ 0.05, and FDR ≤ 0.05). Hierarchical clustering was performed based on differentially expressed mRNAs and IncRNAs using Cluster_Treeview software. The microarray analysis was performed by KangChen Bio-tech, Shanghai, China.

Gene ontological and pathway analysis
The Gene Ontology (GO) project provided a controlled vocabulary to describe gene and gene product attributed in any organism (http://www.geneontology.org). The ontology covers three domains: biological process, cellular component, and molecular function. Fisher’s exact test was used to determine whether the overlap between the differentially expressed list and the GO annotation list was greater than that expected by chance. The lower the P value was the more significant in the GO term enrichment among differentially expressed genes (P value ≤ 0.05 was recommended).

Pathway analysis was a functional analysis that mapped genes to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways (http://www.genome.jp/kegg/). The P value (EASE-score, Fisher P value, or hypergeometric P value) denoted the significance of the pathway correlated to the condition. The GO and KEGG pathways were analyzed by KangChen Bio-tech, Shanghai, China.

CNC analyses and ceRNA analyses
A coding/non-coding gene co-expression network using 21 mRNAs and the differentially expressed IncRNAs were constructed. The CNC analysis was based on calculating the Pearson correlation coefficient between the expression of coding and noncoding genes. Two correlated genes were screened based on the Pearson correlation using the selection parameters PCC ≥ 0.99 and FDR < 0.05. The co-expression network was illustrated using Cytoscape (v3.4.0). Analyses were performed by KangChen Bio-tech, Shanghai, China.

The potential miRNA response elements were searched on the sequences of LncRNAs and mRNAs. The miRNA binding sites were predicted by miRcode (http://www.mircode.org/), and the miRNA-mRNA interaction was predicted by Targetscan (http://www.targetscan.org/).

RNA isolation and qRT-PCR analyses
RNA isolation and qRT-PCR analyses were performed. The primers to amplify SNHG7: forward, 5′-TTGCC TGGCGTCTCGGTTAAT-3′; reverse, 5′-GGAAGTC CATCACAGGCAGAA-3′; GALNT7: forward, 5′-GGTA CCAT GGCCTCATGTTG-3′; reverse, 5′-GCCACCCACA CTGCCCATATCT-3′; miR-34a: forward, 5′-CAGCT GACTC GGGCCATTGGAAGATTTT-3′; reverse, 5′-CTGCTTACAGTGCTATCTTCCC CTTGCG-3′; U6: forward 5′-CTCCGCTTCGGCCAGCAC-3′; reverse 5′-A CCGTTC CACGAATTGCGCT-3′; GAPDH: forward 5′-AACGTGTCAGTGGTGGACCTG-3′; reverse, 5′-AG TGGGGTCTCGTCTTGTGAAGT-3′; miR-34a was normalized to U6, lncRNA-SNHG7 and mRNA expression data were normalized to GAPDH. The relative expression was calculated using the 2-ΔΔCT method.

Plasmids, oligonucleotides, siRNA, transfection, and dual luciferase assay
SNHG7 pcDNA3.1 vector (SNHG7), GALNT7 pcDNA3.1 vector (GALNT7), and empty vector (vector) were subcloned into the expression vector pcDNA3.1 (Invitrogen, USA). MiR-34a mimic, negative control oligonucleotides (miR-NC), miR-34a inhibitor, negative control oligonucleotide (NC inhibitor), small interfering RNA of SNHG7 or GALNT7 (siSNHG7, siGALNT7), and scramble siRNA of SNHG7 or GALNT7 (siSCR) were purchased from Ribobio (Guangzhou, China). The cells were seeded into six-well plates, and transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruction. ShSCR and shSNHG7 were purchased from Ribobio (Guangzhou, China) and constructed into CRC cell lines for further in vivo experiments. The transfection efficiency was evaluated by fluorescence microscopy by calculating the percentage of fluorescein-labeled cells.

Cells were cultured overnight until 70–80% confluence. Next, cells were co-transfected with pcDNA3.1 SNHG7-wt, pcDNA3.1 SNHG7-mut, pGEX3.1 GALNT7-wt or pGEX3.1 GALNT7-mut and empty vector together with miR-34a mimic or the control, respectively. Lipofectamine 2000 (Invitrogen Co., Carlsbad, CA, USA) was used according to the manufacturer’s instructions. After 48 h, cells were harvested for luciferase detection using the dual-luciferase reporter gene assay system (Promega, Madison, WI, USA). All values were obtained
from at least three independent repetitions of the transfection.

**RNA immunoprecipitation (RIP) assay**

RIP assay was performed using the Magna RIP™ RNA Binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA). Cells were collected and lysed in complete RIPA buffer containing a protease inhibitor cocktail and RNase inhibitor. Next, the cell extracts were incubated with RIP buffer containing magnetic bead conjugated with human anti-Ago2 antibody (Millipore) or mouse immunoglobulin G (IgG) control. The protein was digested with proteinase K, and subsequently, the immunoprecipitated RNA was obtained. The purified RNA was finally subjected to a qRT-PCR analysis to demonstrate the presence of the binding targets.

**Ethynyldeoxyuridine (Edu) analysis**

Edu detection kit (KeyGENBioTECH, Nanjing, China) was used to assess cell proliferation. Cells were cultured in 96-well plates at 4 × 10^4 cells/well. Twenty-micromolar Edu labeling media was added to the 96-well plates, and they were then incubated for 2 h at 37 °C under 5% CO₂. After treatment with 4% paraformaldehyde and 0.5% Triton X-100, the cells were stained with an anti-Edu working solution.

**Viability assay, colony formation assay, and tumorigenicity assays in nude mice**

The cell viability was monitored using the Cell Counting Kit-8 (CCK8) according to the manufacturer’s protocol. Measured the OD (optical density) value by microplate computer software (Bio-Rad Laboratories, Hercules, CA). Absorbance at 450 nM (A450) was read on a microplate reader (168–1000 Model 680, Bio-Rad).

Colony formation assay was performed to measure the capacity of cell proliferation. Briefly, 1 × 10^4 cells were plated in six-well plates. After incubated for 12 days, cells were fixed, stained, photographed, and analyzed.

Tumorigenicity assays in nude mice were performed. Briefly, the mice in groups were inoculated subcutaneously with 1 × 10^7 cells in the right flank with SNHG7, shSNHG7, or control. Tumor volumes were calculated by using the equation volume (mm^3) = A × B^2/2, where A is the largest diameter, and B is the perpendicular diameter.

**Cell cycle analysis and apoptosis analysis**

Cell cycle and apoptosis analysis were cultured as previously described [16].

**Wound healing, transwell migration, transwell invasion, and endothelial tube formation assay**

Wound healing assay was performed to measure the capacity of cell migration. Detailed description of wound healing assay was cultured as previously describe [16]. The results were photographed using an inverted microscope (Olympus, Japan) and analyzed by software IPP Image-Pro Plus 6.0.

Transwell assay was performed using Boyden chambers containing a transwell membrane filter (Corning, New York, USA). Transwell assay analysis was cultured as previously described [16]. Evaluation of invasive capacity was performed by counting invading cells under a microscope (40 × 10). Five random fields of view were analyzed for each chamber.

Detailed description of angiogenesis assay was cultured as previously described [16] and analyzed by ImageJ software (National Institutes of Health, Bethesda, MD).

**Western blot analysis**

Western blot analysis was cultured as previously described [16]. GALNT7 monoclonal antibody (1:1000, Abcam, Cambridge, UK), PI3K, p-PI3K Tyr458, Akt, p-Akt Ser473, mTOR, p-mTOR Ser2248 antibody (1:1000 Proteintech, Chicago, USA). Immunoreactive bands were visualized using ECL Western blotting kit (Amersham Biosciences, Buckinghamshire, UK) and were normalized to GAPDH.

**Statistical procedures**

The data were presented as the mean ± SD. Comparison between two groups was assessed using an unpaired two-tailed t test. A one-way analysis of variance, the chi-square test, and the Fisher’s exact test were performed. The survival curves were calculated using the Kaplan-Meier method, and the differences were assessed by a log-rank test. The Cox proportional hazards model was used to determine the independent factors. p value < 0.05 was considered to be statistically significant. All results were reproduced across triplicate experiments. Statistical analyses were carried out using GraphPad Prism (GraphPad Software, Inc., USA).

**Results**

**Expressional profiles of lncRNAs and mRNAs in CRC cell lines**

Microarray analysis revealed lncRNAs and mRNAs expression in CRC cells. After screening (fold change ≥ 2.0, *p value < 0.05), 2130 lncRNAs (1175 were upregulated, and 955 were downregulated) notably changed in metastatic cell SW620 relative to primary cell SW480 (Fig. 1a). A total of 3442 mRNAs (1771 were upregulated, and 1671 were downregulated) significantly changed (Fig. 1b). The top 10 upregulated and downregulated lncRNA/
mRNAs were listed in Table 1, respectively. Function of upregulated lncRNAs would be discussed. GO analysis showed that the aberrant mRNA mainly took part in following biological processes in CRC. The upregulated transcripts involved in regulation of cell proliferation, plasma membrane region, and chemokine receptor binding (Fig. 1c). KEGG pathway enrichment analysis of mRNAs with the top 10 enrichment scores was useful to reveal related pathways and molecular interaction. These results demonstrated that the upregulated and downregulated mRNAs were associated with 10 pathways (Fig. 1d). MTOR pathway was one of the most upregulated pathways.

Gene co-expression network was constructed to study the relationship between the lncRNAs and mRNAs. One hundred ninety-one lncRNAs (116 were upregulated and 76 were downregulated) and 21 mRNAs (9 were upregulated and 12 were downregulated) were involved in the co-expression network (Fig. 1e). The CNC networks indicated that mRNA was correlated with lncRNAs. CeRNA hypothesis showed RNA transcripts could cross-talk by competing for miRNAs. The ceRNA network of...
IncRNA-SNHG7 was first built by integrating expression profiles and regulatory relationships of mRNAs, miRNAs, and SNHG7 (Fig. 1f).

**LncRNA SNHG7 is upregulated in CRC tissues and cell lines and correlated with poor progression**

The microarray results showed that SNHG7 level was significantly higher in SW620 than in SW480 cells. To further explore SNHG7 expression, CRC cell lines were validated. SNHG7 expression was significantly higher in SW620 cells than in SW480 cells (Fig. 2a). In parallel, SNHG7 level was also higher in CRC tissues than that in adjacent tissues (Fig. 2b, c).

In order to examine the correlation between SNHG7 level and clinical pathological features, we stratified 53 tumor tissue samples (cohort 1) into high and low expression groups (Table 2) and found that SNHG7 expression was significantly correlated with tumor size (< 5 vs. ≥ 5 cm, P = 0.025), lymphatic metastasis (absent vs. present, P = 0.002), distant metastasis (absent vs. present, P = 0.004), and tumor stage (I/II vs. III/IV P = 0.002, Fig. 2d–g). Multivariate analysis indicated that SNHG7 expression (95% CI 1.035–5.268; P = 0.011), and tumor stage (95% CI 1.301–6.684; P = 0.002) were independent predictors of the prognosis of CRC (Table 3).

To understand the prognostic value of SNHG7, the overall survival (OS) and disease-free survival (DFS) rates were analyzed. High expression of SNHG7 had poorer prognosis than low expression of SNHG7 (P = 0.0105, OS, and P = 0.0043, DFS, Fig. 2h, i) by Kaplan-Meier and log-rank test analyses. These results implied that SNHG7 overexpression might be useful for the novel prognostic markers in CRC.

**SNHG7 mediates CRC cell proliferation, cell cycle progression, and apoptosis in vitro**

To investigate the biological significance of SNHG7 in CRC progression, the cell proliferation was analyzed. Following SNHG7 overexpression, the proliferative capability of CRC cell lines was increased using CCK8 assay (Fig. 3a), clone formation (Fig. 3b), and Edu staining (Fig. 3c). Knockdown of SNHG7 attenuated the proliferative ability. In addition, the cell cycle was analyzed following SNHG7 overexpression or silencing by fluorescence-activated cell sorting (FACS). G1/S phase was driven in SW480 cell transfected with SNHG7,

### Table 1 The top 10 upregulated and downregulated lncRNAs

| Upregulated lncRNAs | Downregulated lncRNAs |
|---------------------|------------------------|
| Sequence name       | Gene symbol             | Fold change | Sequence name       | Gene symbol             | Fold change |
| NR_024543           | SNHG7                   | 19.3        | NR_03203            | HOXB-AS3                | 32.1        |
| NR_038108           | SNHG16                  | 18.5        | T105469             | G024903                 | 25.4        |
| T117110             | G027615                 | 17.2        | NR_033877           | LINC00548               | 19.8        |
| T117111             | G027616                 | 15.8        | T377350             | G089269                 | 14.8        |
| ENST00000606186     | RF4-680D5.8             | 9.1         | NR_039989           | MIR4458HG               | 11.0        |
| ENST00000430859     | AC005083.1              | 9.0         | NR_110078           | UBXN10-AS1              | 10.7        |
| NR_109758           | LOC644919               | 8.3         | NR_110845           | LOC101928674            | 10.7        |
| TCNS_00019861       | XLOC_009079             | 7.2         | NR_120685           | LINC01503               | 10.5        |
| ENST0000062999      | RP11-395P17.11          | 7.1         | T232938             | G053602                 | 10.1        |
| NR_034119           | LINC00460               | 6.9         | NR_034121           | CKMT2-AS1               | 9.2         |

| Upregulated mRNAs   | Downregulated mRNAs    |
|---------------------|------------------------|
| Gene symbol         | Fold change            | Gene symbol         | Fold change |
| LCP1                | 90.2                   | IGFBP3              | 59.3        |
| S100P               | 60.6                   | GLI3                | 56.5        |
| CNN3                | 50.8                   | PTGR1               | 46.2        |
| TPM2                | 46.6                   | ISM2                | 44.3        |
| GALNT7              | 43.7                   | ZAP70               | 37.7        |
| GALNT1              | 40.6                   | RGCC                | 33.1        |
| CA9                 | 39.9                   | ARL4C               | 33.1        |
| GYLT1B              | 34.4                   | CADM1               | 32.9        |
| GPX2                | 32.0                   | TBC1D4              | 30.8        |
| MFNG                | 31.9                   | KRT85               | 27.8        |
whereas stalled G1/S was observed in SW620 cell transfected with siSNHG7 in Fig. 3d. The apoptosis cells were decreased in transfected with SNHG7 group, while in transfected with siSNHG7, SW620 cells had a significantly higher percentage of Annexin V-positive cells by FACS analysis (Fig. 3e). Furthermore, upregulation of SNHG7 led to reduced levels of cleaved caspase 3 and cleaved PARP in SW480 cells, and opposite trend was found in SW620 cells transfected with siSNHG7 compared with siSCR (Fig. 3f). These data indicated that SNHG7 promoted cell proliferation, facilitated cell cycle progression, and inhibited apoptosis in vitro.

**SNHG7 promotes CRC cell migration, invasion, vasculogenic mimicry in vitro, and proliferation in vivo**

To measure the migratory and invasive ability of CRC cells, wound healing and transwell assays were utilized. The results showed that the ability of migration and invasion were increased in SW480 cell transfected with SNHG7, while the migratory and invasive ability were
decreased in SW620 cell transfected with siSNHG7 (Fig. 4a–c).

It is well known that new blood vessel is essential in tumor development. The endothelial tube formation assay was used to assess the ability of SNHG7 in CRC cell progression. The results showed that neovascularization rate was increased after transfecting with SNHG7 or decreased after transfecting with siSNHG7 compared with their negative controls (Fig. 4d).

To confirm whether SNHG7 affect CRC tumorigenesis, SW480 cells (transfected with SNHG7 or NC) and SW620 cells (transfected with shSNHG7 or shSCR) were inoculated into nude mice. As shown in Fig. 4e, f, tumor growth in SNHG7 group was significantly faster than that in NC group, while tumor growth was slower in shSNHG7 group than that in shSCR group. Furthermore, the average tumor weight was obviously changed than their corresponding control group. In order to further validate the growth ability mediated by SNHG7 in vivo, the tumor tissues were for IHC staining with ki67 antibody. These results were consistent with our above data that SNHG7 overexpression enhanced the growth and downregulation of SNHG7 decreased the tumor growth of CRC cell lines (Fig. 4g, h). Collectively, these data demonstrated that SNHG7 promoted CRC cell progression.

SNHG7 is a direct target of miR-34a and regulates GALNT7 expression in CRC cell lines

Recently, accumulating evidence has suggested that IncRNA has an inhibitory effect on miRNA expression and activity [17]. CeRNA analysis and bioinformatics software (Starbase v2.0) were used to predict the potential miRNA binding sites in SNHG7. We found that miR-34a was among the numerous possible targets of SNHG7 (Fig. 5a). MiR-34a level was much lower in CRC tissues than that in adjacent tissues (Fig. 5b). Pearson correlation coefficient analysis showed a significant negative correlation between SNHG7 and miR-34a in CRC tissues (Fig. 5c). The luciferase activity of wt-SNHG7 was significantly reduced by miR-34a mimic (Fig. 5d). In contrast, the luciferase activity of mut-SNHG7 experienced no statistical changes. These findings indicated that there were interaction between miR-34a and the binding sites of SNHG7.

The previous study indicated that lncRNAs might act as the sponge of miRNAs and function through binding the miRNAs and Argonaute 2 (Ago2) [18, 19]. According to the bioinformatics software, the sites of SNHG7/miR-34a could also bind the protein Ago2 protein. So, RIP assay was performed in SW480 and SW620 cell extracts utilizing the antibody against Ago2. SNHG7 and miR-34a expression were detected by qRT-PCR. The results illustrated that both SNHG7 and miR-34a were enriched in the Ago2 pellet relative to control IgG immunoprecipitate (Fig. 5e), suggesting that SNHG7 was present in Ago-contained miRNPs, likely through an association with miR-34a.

### Table 2 Relationship between SNHG7 expression and clinicopathologic parameters of 53 colorectal cancer patients (cohort 1)

| Characteristics          | Number of case | SNHG7 expression | P value |
|--------------------------|----------------|------------------|---------|
|                          |                | High (n = 30) %  | Low (n = 23) % |
| Age (years)              |                |                  |         |
| < 60                     | 27             | 14               | 13      |
| > 60                     | 26             | 16               | 10      |
| Gender                   |                |                  |         |
| Male                     | 33             | 17               | 16      |
| Female                   | 20             | 13               | 7       |
| Tumor size               |                |                  |         |
| < 5 cm                   | 23             | 9                | 14      |
| ≥ 5 cm                   | 30             | 21               | 9       |
| Tumor location           |                |                  |         |
| Colon                    | 29             | 17               | 12      |
| Rectum                   | 24             | 13               | 11      |
| Depth of invasion        |                |                  | 0.194   |
| T1,T2                    | 34             | 17               | 17      |
| T3,T4                    | 19             | 13               | 6       |
| Histologic grade         |                |                  | 0.206   |
| Well/moderately          | 27             | 13               | 14      |
| Poorly/others            | 26             | 17               | 9       |
| Lymphatic metastasis     |                |                  | 0.002** |
| Absent                   | 24             | 8                | 16      |
| Present                  | 29             | 22               | 7       |
| Venous invasion          |                |                  | 0.132   |
| Absent                   | 27             | 18               | 9       |
| Present                  | 26             | 12               | 14      |
| Nervous invasion         |                |                  | 0.414   |
| Absent                   | 31             | 19               | 12      |
| Present                  | 22             | 11               | 11      |
| Distant metastasis       |                |                  | 0.004** |
| Absent                   | 32             | 13               | 19      |
| Present                  | 21             | 17               | 4       |
| Tumor stage*             |                |                  | 0.002** |
| I and II                 | 26             | 9                | 17      |
| III and IV               | 27             | 21               | 6       |

*Tumor stage was obtained according to the TNM criteria

**P<0.05

Li et al. Journal of Hematology & Oncology (2018) 11:89
Page 8 of 17
Gene co-expression networks indicated that SNHG7 was correlated with nine mRNAs (B3GLCT, FUT2, MFNG, MGAT4A, GALNT1, GALNT5, GALNT7, ST3GAL5, ST6GALNAC2). GALNT7 was the highest correlation among these mRNAs in Pearson analysis. GALNT7 level was identified in CRC tissues and metastasis cell lines (Fig. 5f, g), and a positive relationship between the levels of SNHG7 and GALNT7 mRNA was found (Fig. 5h). The expression of GALNT7 mRNA and protein were significantly increased in SW480 cells overexpressing SNHG7 (Fig. 5i). In contrast, GALNT7 level was downregulated in SW620 cells with silencing SNHG7 (Fig. 5j). These results showed that SNHG7 indeed regulated GALNT7 level.

GALNT7 is a target gene of miR-34a in CRC cell lines
Lately, ceRNA hypothesis was proposed to describe the crosstalk of RNA transcripts with each other by using MREs. LncRNAs participate in ceRNA networks and mRNA-miRNA-lncRNA crosstalk [20]. We initially identified GALNT7 as potential target of miR-34a using public prediction algorithms (Target-Scan, miroRNA.org and Starbase v2.0) (Fig. 6a). Then, Pearson analysis showed a negative correlation with miR-34a and GALNT7 in CRC samples (Fig. 6b). Next, the dual luciferase reporter assay revealed that GALNT7 was the direct target of miR-34a (Fig. 6c).

To verify the phenomenon of mRNA and lncRNA competed for the binding of miRNA, GALNT7 expression was analyzed. The GALNT7 level was higher in SW480 cell transfected with Wt-SNHG7 than that transfected with Mut-SNHG7 (Fig. 6d). The influence of Wt-SNHG7 could be reversed by transfecting miR-34a mimic in SW480 cells, which identified that SNHG7 regulated GALNT7 by sponging for miR-34a. SNHG7 knockdown led to a decreased GALNT7 expression, while GALNT7 level could be reversed by co-transfecting siSNHG7 and miR-34a inhibitor in SW620 cells (Fig. 6e).

SNHG7 or GALNT7 and miR-34a mimic were co-transfected into SW480 cells; the ability of proliferation, migration, invasion, and vasculogenic mimicry were recovered (Fig. 6f). By contrary, knockdown of SNHG7 or GALNT7 expression weakened the proliferation and metastasis in SW620 cells. Suppression of miR-34a relieved the reduced level of SNHG7 or GALNT7 (Fig. 6g). All of the outcomes above explained that SNHG7 functioned as a ceRNA to regulate GALNT7 expression by sponging miR-34a in CRC progression.

SNHG7 activates the PI3K/AKT/mTOR pathway
KEGG pathway enrichment analysis identified that mTOR pathway was one of the most enriched pathways, involved in the development of CRC. In order to figure out the molecular mechanism induced by SNHG7, miR-34a, and GALNT7, the activity of PI3K/AKT/mTOR pathway was detected in the SW480 and SW620 cells. The results showed that high levels of p-PI3K, p-Akt, and p-mTOR were observed in SW480 cells transfected with SNHG7 or GALNT7 than control groups, respectively. The degree of PI3K/Akt/mTOR pathway was decreased in SW480 cell transfected with miR-34a mimic (Fig. 7a, c). Correspondingly, the expression of PI3K/Akt/mTOR pathway proteins was decreased in SW620 cell transfected with siSNHG7 or siGALNT7 (Fig. 7b, d).

SW620 cells treated with LY294002 or siSNHG7 exhibited apparently decreased levels of the main signal molecules of PI3K/Akt/mTOR pathway (Additional file 1: Figure S1a). The inhibition of PI3K/Akt/mTOR pathway resulted in decreased

| Variables | Subset | Univariate analysis | Multivariate analysis |
|-----------|--------|---------------------|----------------------|
|           |        | HR (95% CI)         | P value              | HR (95% CI)         | P value |
| Age (years) | < 60 vs. ≥ 60 | 1.379(0.525–2.484) | 0.495                | –                    | –         |
| Gender     | Male vs. female | 1.514(0.701–2.916) | 0.410                | –                    | –         |
| Tumor size | < 5 cm vs. ≥ 5 cm | 2.438(1.003–5.105) | 0.062                | –                    | –         |
| Tumor location | Colon vs. rectum | 1.028(0.712–1.582) | 0.875                | –                    | –         |
| Histologic grade | Well/moderately vs. poorly/others | 1.847(0.571–2.896) | 0.289                | –                    | –         |
| Depth of invasion | T1,T2 vs. T3,T4 | 2.561(0.911–4.616) | 0.124                | –                    | –         |
| Lymphatic metastasis | Absent vs. Present | 3.054(1.008–5.531) | 0.028*               | 2.313(0.869–4.012) | 0.045*    |
| Venous invasion | Absent vs. Present | 1.478(0.491–3.292) | 0.353                | –                    | –         |
| Distant metastasis | Absent vs. Present | 3.681(1.308–5.928) | 0.004*               | 3.163(1.586–2.725) | 0.011*    |
| Tumor stage | I–II vs. III–IV | 4.422(1.849–8.241) | < 0.001*             | 3.549(1.301–6.684) | 0.002*    |
| SNHG7 expression | Low vs. high | 3.317(1.331–5.609) | 0.008*               | 2.924(1.035–5.268) | 0.030*    |

HR hazard ratio, CI confidence interval
*P<0.05

Table 3 Univariate and multivariate Cox regression analyses of clinicopathological features association with prognosis of 53 CRC patients (cohort 1)
proliferation and invasion of SW620 cells (Additional file 1: Figure S1b). These data suggested that the SNHG7, miR-34a, and GALNT7 played an important role in CRC progression via PI3K/AKT/mTOR pathway.

**Discussion**

Early diagnosis, especially biomarkers, is an effective means to reduce the mortality of CRC patients. In this study, we explored the possible mechanism of lncRNA-SNHG7, as competing endogenous RNA, modulating GALNT7 by sponging miR-34a in human CRC cell lines.

LncRNAs exerted more complex effects on cell proliferation, differentiation, and epigenetic processes [21, 22]. LncRNA-ATB as a biomarker involved in the progression of CRC [23]. LncRNA-CCAT1-L regulated MYC locus in CRC progression [24]. In this study, we used lncRNA microarray to analyze the composition profiling of lncRNAs in CRC cells. The differences in lncRNA expression, especially SNHG7 were found. SNHG7 was
upregulated in CRC tissues and metastatic cell lines. Furthermore, SNHG7 upregulation was correlated with tumor size, lymphatic metastasis, distant metastasis, and tumor stage of clinicopathologic parameters. The OS and DFS of CRC patients with low expression of SNHG7 were longer than that with high expression of SNHG7. Moreover, SNHG7 promoted CRC cell progression both in vitro and in vivo. Recent studies showed that SNHG7

**Fig. 4** SNHG7 promotes cell migration, invasion, vasculogenic mimicry of CRC cells in vitro, and proliferation in vivo. **a, b** The cell migration rates were determined by performing wound healing and transwell assay. **c** Transwell invasion assays were performed. **d** The abilities of neovascularization were determined by endothelial tube formation assay. **e** Effects of SNHG7 overexpression on tumor growth in vivo. Left: images of tumors in nude mice injected with SNHG7-overexpressed SW480 cells. Middle: tumor weights. Right: tumor growth curves. **f** Effects of SNHG7 knockdown on tumor growth in vivo. Left: images of tumors in nude mice injected with shSNHG7 SW620 cells. Middle: tumor weights. Right: tumor growth curves. **g, h**Ki67 was detected by IHC assay. The error bars in all graphs represented SD, and each experiment was repeated thrice. *P < 0.05, **P < 0.01, ***P < 0.001
was correlated with breast cancer [9], chromophobe renal cell carcinoma [10], and lung cancer [11]. These data suggested that SNHG7 was CRC progression-related. Further investigation was needed to elucidate the role of SNHG7 in CRC.

CeRNA hypothesis emerged as an alternative function for lncRNAs [25]. The novel regulatory mechanism has been identified in crosstalk between lncRNAs and mRNAs. LncRNA HULC promoted tumorigenesis via the miR-200a-3p/ZEB1 pathway in hepatocellular carcinoma.
LncRNA RSU1P2, acting as a ceRNA against let-7a, promoted tumorigenesis in cervical cancer [27]. Our current research observed an inverse correlation between SNHG7 and miR-34a. MiR-34a could bind the SNHG7 by conducting the dual luciferase assay. Also, we found an endogenous interaction between SNHG7 and miR-34a by utilizing RIP assays with the Ago2 antibody in CRC cells. SNHG7 regulated CRC cell progression partially mediated by miR-34a, which was highly correlated with CRC malignancy [28].

Aberrant O-glycosylation is a hallmark of metabolic disorders and many cancers. Altered cell-surface O-glycoproteins are often implicated in proliferation, invasion, and metastasis [29]. GALNTs were illustrated as the importance in cancer progression. Fig. 6 GALNT7 is a target gene of miR-34a in CRC cells. a Sequence alignment of miR-34a with the binding sites in the wild-type and mutant-type regions of GALNT7 was shown. b The negative relevance between miR-34a and GALNT7 expression was revealed by Pearson’s correlation curve. c The relative luciferase activity of 293T cells was tested after co-transfection with GALNT7 wide-type and miR-34a mimic. d GALNT7 level in SW480 cells co-tranfected with SNHG7 and miR-34a mimic was analyzed. e GALNT7 level in SW620 cells co-transfected with siSNHG7 and miR-34a inhibitor was shown. f, g SNHG7 and GALNT7 competing to bind with miR-34a were identified by function screen analysis in SW480 and SW620 cells. The error bars in graphs represented SD, and each experiment was repeated thrice. *P < 0.05, **P < 0.01.
pathogenesis. The GALNT levels vary with cell type, differentiation, and malignant transformation [30, 31]. GALNT12 mutation inactivated the normal function of the GALNT enzyme in initiating mucin type O-linked protein glycosylation in colon cancers [32]. MiRNA cluster controlled glycosylation by targeting GALNTs, responsible for initiating mucin-type O-linked glycosylation [33]. Aberrant glycosylation resulting from GALNT1 involved in melanoma [34], ovarian [35], and bladder cancers [36]. Overexpression of GALNT2 inhibited IGF-I-stimulated growth, migration, and invasion of neuroblastoma cells [37]. GALNT3 was predicted as an independent prognostic factor in renal cell carcinomas [38], and GALNT6 was found to function in pancreatic cancer [39]. Upregulation of GALNT5 played a major role in hepatoblastoma progression [40]. GALNT7, as a downstream target of miR-34a, encoded GalNAc-transferase 7 to participate in laryngeal squamous cell carcinoma [13]. Several studies have reported the function of GALNT7 in the regulation of hepatocellular carcinoma [41] and cervical cancer [14]. These findings suggested that genetic defects in the O-glycosylation in part underlied aberrant glycosylation in CRC. In our study, GALNT7 expression was increased in metastatic CRC cells and tumor tissues. Therefore, GALNT7 implicated as a prognostic marker and therapeutic target for CRC.

In recent years, miRNAs could serve functionally as oncogenes or tumor suppressors in cancers. MiR-30e regulated GALNT7 transcripts in cervical cancer [42]. MiR-34a was downregulated in colon cancer specimens compared to normal colonic mucosa [43]. MiR-30a-5p regulated GALNT7 transcripts in renal cell carcinoma [44]. In this study, miR-34a also regulated endogenous GALNT7 expression in CRC cell lines and directly
targeted GALNT7. LncRNAs played a part in ceRNA networks and LncRNA-miRNA-mRNA crosstalk. SNHG7 and GALNT7 were constructed in gene co-expression networks, and SNHG7 could regulate GALNT7 level. MiR-34a directly targeted SNHG7-3′ UTR. Altered levels of SNHG7, miR-34a, and GALNT7 were associated with progression of CRC cells. Taken together, these data indicated that SNHG7 participated in ceRNA networks and SNHG7-miR-34a-GALNT7 crosstalk played a vital role in CRC progression.

PI3K/Akt/mTOR pathway is known to control the progression of cancer [45]. SNHG7 has potential to influence ribosome biogenesis, which could regulate mTOR transcription [46]. MiR-34a could regulate diffuse malignant peritoneal mesothelioma progression by modulating Akt [47]. CRC cell lines SW480 and SW620 with differently metastatic potential were used in this study. SNHG7, miR-34a, and GALNT7 expression altered between SW480 and SW620 cells. SNHG7 acted as ceRNA to regulate miR-34a availability for the target gene GALNT7, which modulated the PI3K/Akt/mTOR pathway. LY294002 represented the first generation inhibitors with highly potent PI3K-inhibitory property [48]. The inhibition of PI3K/Akt/mTOR pathway by LY294002 or siSNHG7 altered proliferative and invasive abilities of SW620 cells. Therefore, targeting the SNHG7/miR34a/GALNT7 interaction might represent a novel therapeutic application, thus contributing to the metastatic mechanism in CRC patients.

Our study defined a mechanism for the regulatory function of SNHG7 and miR-34a modulating GALNT7 expression in Fig. 8. The identification of these ceRNAs will undoubtedly enhance our knowledge to clarify the mechanism of SNHG7-miR-34a-GALNT7 axis involving in CRC progression.

Conclusion

In summary, our study showed that SNHG7 as a ceRNA to regulated GALNT7 by sponging miR-34a in CRC and played the oncogenic role in regulating PI3K/Akt/mTOR pathway. Targeting the SNHG7/miR34a/GALNT7 interaction may represent a novel therapeutic application, thus contributing to better knowledge of the metastatic mechanism in CRC patients.

Additional file

Additional file 1: Figure S1. PI3K/Akt/mTOR pathway inhibition modulates the proliferation and invasion of SW620 cells. (a) SW620 cells were treated LY294002 or siSNHG7. The main molecular expression of
The authors declare that they have no competing interests.

Competing interests
Not applicable.

Consent for publication
in agreement with institutional guidelines. Informed consent was obtained from all participants included in the study, First Affiliated Hospital of Dalian Medical University (YJ-KY-FB-2016-16), and The study has been examined and certified by the Ethics Committee of the responsible for designing the experiments and study supervision. All authors material support. YS and BL provided and collected the clinical data. LJ was analysis and drafted the manuscript. JH and YP provided technical and YL and CZ were responsible for doing experiments, acquisition of data, and their contributions.

Authors’ contributions
YL and CZ were responsible for doing experiments, acquisition of data, and their contributions.

Ethics approval and consent to participate
The study has been examined and certified by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (YJ-KY-FB-2016-16), and informed consent was obtained from all participants included in the study, in agreement with institutional guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Brawley O, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
2. O’Brien JM. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Waldau, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hennminki. N Engl J Med 343:78–84, 2000. Survey of ophthalmology, 2000;45:167–8.
3. Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.
4. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:462–9.
5. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A cellRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–8.
6. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:257–65.
7. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie T, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004;36:40–5.
8. Quinn L, Finn SP, Cuffe S, Gray SG. Non-coding RNA repositories in malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands). 2015;90:417–26.
9. Zhou M, Zhong L, Xu W, Sun Y, Zhang Z, Zhao H, et al. Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Sci Rep. 2016;6:31038.
10. He HT, Xu M, Kuang Y, Han XY, Wang MQ, Yang Q. Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma. Onco Targets Therapy. 2016;9:6399–406.
11. She K, Huang J, Zhou H, Huang T, Chen G, He J. IncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAK-M2 expression. Oncol Rep. 2016;36:2673–80.
12. Khoury GA, Baliban RC, Floudas CA. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011;1:90.
13. Li W, Ma H, Sun J. MicroRNA34a/c function as tumor suppressors in Hep2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol Med Rep. 2014;9:1293–8.
14. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase. J Biol Chem. 2012;287:14301–9.
15. Tanouchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, et al. Overexpression of GaINAc-transferase GaINAc-T3 promotes pancreatic cancer cell growth. Oncogene. 2011;30:4843–54.
16. Shen Y, Liu Y, Zhao L, Liu B, Li Y, Jia L. MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1. Int J Biochem Cell Biol. 2017;90:48–58.
17. Jalali S, Bhatiya D, Lakwani MK, Sivasubbu S, Scaria V. Systematic transcriptome wide analysis of IncRNA-miRNA interactions. PLoS One. 2013;8:e55823.
18. Prinsen JR, Chinnaiyan AM. The emergence of IncRNAs in cancer biology. Cancer Discov. 2011;1:391–407.
19. Thomas M, Lieberman JA, Lai A. Desperately seeking microRNA targets. Nat Struct Mol Biol. 2010;17:1169–74.
20. Qu J, Li M, Zhong W, Hu C. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med. 2015;8:17110–6.
21. Hauptman N, Glavac D. Long non-coding RNA in cancer. Int J Mol Sci. 2013;14:4655–69.
22. Maass PG, Luft FC, Bahrung S. Long non-coding RNA in health and disease. J Mol Med (Berlin, Germany). 2014;92:337–46.
23. Iuchi T, Uchi R, Nambara S, Sato T, Komatsu H, Hirata H, et al. A long noncoding RNA, IncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015;35:1385–8.
24. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L IncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24:513–31.
25. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk. Nature. 2014;505:344–52.
26. Li SP, Xu HK, Yu Y, He JD, Wang Z, Xu YJ, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEBr1 signaling pathway. Oncotarget. 2016;7:42431–46.
27. Liu Q, Guo X, Que S, Yang X, Fan H, Liu M, et al. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget. 2016;7(27):43768–81.
28. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104:15472–7.
29. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60.
30. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012;22:736–56.
31. Schjoldager KT, Clausen H. Site-specific protein O-glycosylation modulates proprotein processing—deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim Biophys Acta. 2012;1820:2079–94.
32. Guda K, Moínova H, He J, Jamison O, Ravi L, Natale L, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A. 2009;106:12921–5.
33. Gaziel-Sovran A, Hernando E. miRNA-mediated GALNT modulation of invasion and immune suppression: a sweet deal for metastatic cells. Oncoimmunology. 2012;1:746–8.
34. Cheng SL, Huang Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ. Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biopharm Bull. 2006;29:655–69.
35. Phelan CM, Tai Y, Goode EL, Verkant RA, Fridley BL, Beesley J, et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomark Prev. 2010;19:600–4.
36. Ding MX, Wang HF, Wang JS, Zhan H, Zuo YG, Yang DL, et al. ppGalNAc T1 as a potential novel marker for human bladder cancer. Asian Pac J Cancer Prev. 2012;13:5653–7.
37. Ho WL, Chou CH, Jeng YM, Lu MY, Yang YL, Jou ST, et al. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget. 2014;5:12247–59.
38. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, et al. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 2013;109:472–81.
39. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011;104:882–9.
40. Rodrigues TC, Fidalgo F, da Costa CM, Ferreira EN, da Cunha IW, Carrano DM, et al. Upregulated genes at 2q24 gains as candidate oncogenes in hepatoblastomas. Future Oncol (London, England). 2014;10:2449–57.
41. Shan SW, Fang L, Shateva T, Rutnam ZJ, Yang X, Wu D, et al. Mature miR-17–5p and passenger miR-17–3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci. 2013;126:1517–30.
42. Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.
43. Wu H, Chen J, Li D, Liu X, Li L, Wang K. MicroRNA-30e functions as a tumor suppressor in cervical carcinoma cells through targeting GALNT7. Transl Oncol. 2017;10:876–85.
44. Li Y, Li Y, Chen D, Jin L, Su Z, Liu J, et al. miR30a5p in the tumorigenesis of renal cell carcinoma: a tumor suppressive microRNA. Mol Med Rep. 2016;13:4085–94.
45. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.
46. Zhang R, Lahens NF, Balance Hl, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014;111:16219–24.
47. El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, et al. Antitumor activity of mir-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signalling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10(1):19.
48. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6:88.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions